This week, three Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
Biogen Idec (NASDAQ:BIIB) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Biogen Idec is a global biotechnology company that meets the needs of therapeutic care providers and recipients. In Portfolio Grader’s specific subcategory of Equity, BIIB also gets an A. Shares of BIIB have increased 11% over the past month, better than the 4.1% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of BIIB stock.
Incyte Corp. (NASDAQ:INCY) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 7.2% over the past month. For more information, get Portfolio Grader’s complete analysis of INCY stock.
This week, 3SBio (NASDAQ:SSRX) pushes up from a C to a B rating. 3SBio is a biotechnology company that engages in the research and development, manufacture, and distribution of pharmaceutical products in the Peoples Republic of China. For more information, get Portfolio Grader’s complete analysis of SSRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.